Page last updated: 2024-08-22

vidarabine and Lymphoma, T Cell, Peripheral

vidarabine has been researched along with Lymphoma, T Cell, Peripheral in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheson, BD	1
Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J	1
Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S	1
Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M	1
Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM	1
Boehrer, S; Chow, KU; Engels, K; Hansmann, ML; Harder, L; Hinz, T; Hoelzer, D; Janssen, O; Kabelitz, D; Kriener, S; Mitrou, PS; Rummel, MJ; Siebert, R; Weidmann, E	1

Reviews

1 review(s) available for vidarabine and Lymphoma, T Cell, Peripheral

Article	Year
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Current opinion in hematology, 2009, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine	2009

Trials

1 trial(s) available for vidarabine and Lymphoma, T Cell, Peripheral

Article	Year
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting	2012

Article

Year

Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.

Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting

2012

Other Studies

4 other study(ies) available for vidarabine and Lymphoma, T Cell, Peripheral

Article	Year
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. European journal of haematology, 2006, Volume: 76, Issue:6 Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine	2006
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. International journal of hematology, 2006, Volume: 83, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine	2006
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine	2008
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine. Onkologie, 2001, Volume: 24, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Vidarabine	2001